Diagnostics & Research industry stocks
44 companies in the Diagnostics & Research industry. 32 have a published intrinsic value and 3 trade at least 20% below it.
The median company in Diagnostics & Research with a published value trades 107% above our estimate of intrinsic value.
Values as of the 22 Sept 2026 close.
Most undervalued stocks in Diagnostics & Research
Liquid names only: at least $1M traded a day and $50M of market value.
Largest companies in Diagnostics & Research
- Thermo Fisher Scientific Inc (TMO): overvalued, -138% margin of safety
- Danaher Corp (DHR): overvalued, -137% margin of safety
- Natera Inc (NTRA): overvalued, -573% margin of safety
- Agilent Technologies Inc (A): overvalued, -105% margin of safety
- IQVIA Holdings Inc (IQV): overvalued, -54% margin of safety
- Waters Corp (WAT): overvalued, -235% margin of safety
- Idexx Laboratories Inc (IDXX): overvalued, -108% margin of safety
- Illumina Inc (ILMN): overvalued, -290% margin of safety
- Mettler-Toledo International Inc (MTD): overvalued, -134% margin of safety
- Quest Diagnostics Inc (DGX): undervalued, +49% margin of safety
- Labcorp Holdings Inc (LH): overvalued, -63% margin of safety
- Guardant Health Inc (GH): overvalued, -1033% margin of safety
- Medpace Holdings Inc (MEDP): overvalued, -41% margin of safety
- Revvity Inc (RVTY): overvalued, -634% margin of safety
- Charles River Laboratories International Inc (CRL): overvalued, -221% margin of safety
- Icon Plc (ICLR): overvalued, -31% margin of safety
- Qiagen NV (QGEN): overvalued, -40% margin of safety
- Radnet Inc (RDNT): overvalued, -884% margin of safety
- Billiontoone Inc (BLLN): not valued
- Sotera Health Co (SHC): overvalued, -44% margin of safety
- GRAIL Inc (GRAL): not valued
- Adaptive Biotechnologies Corp (ADPT): overvalued, -485% margin of safety
- Veracyte Inc (VCYT): overvalued, -32% margin of safety
- Caredx Inc (CDNA): overvalued, -35% margin of safety
- GeneDx Holdings Corp (WGS): overvalued, -167% margin of safety
- Neogenomics Inc (NEO): slightly undervalued, +11% margin of safety
- Freenome Inc (FRNM): no published value
- Personalis Inc (PSNL): overvalued, -796% margin of safety
- Opko Health Inc (OPK): not valued
- Castle Biosciences Inc (CSTL): overvalued, -320% margin of safety
- Fulgent Genetics Inc (FLGT): overvalued, -34% margin of safety
- Myriad Genetics Inc (MYGN): not valued
- Biodesix Inc (BDSX): slightly overvalued, -19% margin of safety
- Exagen Inc (XGN): overvalued, -45% margin of safety
- Burning Rock Biotech Ltd ADR (BNR): not valued
- Insight Molecular Diagnostics Inc (IMDX): not valued
- Quantum Cyber NV (QUCY): no published value
- MDxHealth SA (MDXH): undervalued, +74% margin of safety
- Precipio Inc (PRPO): undervalued, +63% margin of safety
- Advanced Biomed Inc (ADVB): no published value
- BioAffinity Technologies Inc (BIAF): overvalued, -157% margin of safety
- ENDRA Life Sciences Inc (NDRA): no published value
- XWELL Inc (XWEL): not valued
- iSpecimen Inc (ISPC): not valued
Other Healthcare industries
All industries